Combination antigene therapy targeting c-myc and c-erbB2 in the ovarian cancer COC1 cell line

Gynecologic Oncology

Volumn 85, Issue 1, 2002, Pages 40-44

  Fei, Ruan ^a   Shaoyang, Liu ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Antisense; DNA; erbB 2; Genes; Liposomes; Myc; Ovarian neoplasms

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; COMPLEMENTARY DNA; LIPOSOME; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; RNA;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GROWTH INHIBITION; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; ONCOGENE C ERB; ONCOGENE C MYC; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0036229111     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6571     Document Type: Article

References (20)

1. Antisense oligodeoxynucleotides targeted against different reigions of cyclin D mRNA may exert different inhibitory effects on cell growth and gene expression
2. P53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines
3. Evidence supporting a signal transduction pathway leading to the radio-resistant phenotype in human tumor cells
4. Transfection of orarian cancer cells with tumor nerosis factor-α (TNF-α) antisense mRNA abolishes the proliferative response to interleukin-1 but not TNF-2
5. Delivery of antisense oligodeoxynucleotides against the human epidermal growth factor receptor in cultured KB cells with lipsomes conjugates to folate via polyethylen glycol
6. Humanization of an anti-p185 antibody for human cancer therapy
7. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by EIA
8. Value of p-glycoprotein, glutathione S-transferase pi, c-erbB-2 and P53 as prognostic factors in ovarian carcinomas
9. C-myc amplification in ovarian cancer
10. A unique c-myc targeted triplex-forming oligonucleotides inhibits the growth of ovarian and cervical carcinomas in vitro
11. 185-overexpression in ovarian carcinoma cells
12. Hereditary ovarian cancer: Molecular genetics and clinical implications
13. Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines
14. Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model
15. Combination effect of adenovirus-mediated pro-apototic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines
16. Cell death via apoptosis and its relationship to growth, development and differentiation of both tumor and normal cells
17. Regulation of c-myc transcription and mRNA abudance by serum growth factors cell contact
18. Role of three cancers "master genes" P53, bcl-2 and c-myc on the apoptotic process
19. Molecular aspects of ovarian cancer. Is gene therapy the solution?
20. Antisense and antigene properties of peptide nucleic acids